Inhaled long-acting muscarinic antagonists in asthma - A narrative review.
Administration, Inhalation
Adrenal Cortex Hormones
/ therapeutic use
Adrenergic beta-2 Receptor Agonists
/ therapeutic use
Asthma
/ drug therapy
Bronchodilator Agents
/ therapeutic use
Drug Therapy, Combination
Humans
Muscarinic Antagonists
/ therapeutic use
Pulmonary Disease, Chronic Obstructive
/ drug therapy
Asthma
Bronchodilator agents
Cholinergic agents
Muscarinic M3 receptor
Journal
European journal of internal medicine
ISSN: 1879-0828
Titre abrégé: Eur J Intern Med
Pays: Netherlands
ID NLM: 9003220
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
14
10
2020
revised:
20
01
2021
accepted:
24
01
2021
pubmed:
11
2
2021
medline:
24
4
2021
entrez:
10
2
2021
Statut:
ppublish
Résumé
Long-acting muscarinic antagonists (LAMAs) have a recognised role in the management of chronic obstructive pulmonary disease. In asthma, muscarinic antagonists (both short- and long-acting) were historically considered less effective than β
Identifiants
pubmed: 33563506
pii: S0953-6205(21)00033-9
doi: 10.1016/j.ejim.2021.01.027
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Adrenergic beta-2 Receptor Agonists
0
Bronchodilator Agents
0
Muscarinic Antagonists
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
14-22Informations de copyright
Copyright © 2021. Published by Elsevier B.V.